Assessment of baseline characteristics, glycemic control and oral antidiabetic treatment in Asian patients with diabetes: The Registry for Assessing OAD Usage in Diabetes Management (REASON) Asia study (在亚洲糖尿病患者中评估基线特征、血糖控制情况以及口服降糖药物使用情况：使用登记表评估糖尿病治疗中口服药使用情况（REASON）的亚洲研究)

Background To assess baseline characteristics, glycemic control, and treatment with oral antidiabetic drugs (OAD) in type 2 diabetes mellitus (T2DM) patients. Methods This multinational, observational study recruited patients ≥21 years of age who were newly diagnosed and/or treated with OAD monotherapy for <6 months but were inadequately controlled. In cross-sectional phase, data on demographics, medical history, diabetic complications and comorbidities, OAD treatment, glycosylated hemoglobin (HbA1c), and fasting blood glucose (FBG) were collected. In longitudinal phase evaluating 6-month follow-up of sulfonylurea (SU)-treated patients, additional data on reasons for not achieving HbA1c targets were collected. Results Of 1487 patients (mean [±SD] age 52.0 ± 11.6 years; 46.7% men; mean BMI 25.8 ± 4.4 kg/m2) recruited, 75.9% were newly diagnosed, 73.3% had central obesity, 43.8% had hypertension, and 60.5% had dyslipidemia. The mean HbA1c was 9.8 ± 2.4%, and the mean FBG was 11.3 ± 4.3 mmol/L. At T0 (baseline) and T6 (month 6 visit), 99.8% (n = 1066) and 97.1% (n = 830) patients received SU, respectively. There was decrease from T0 to T6 in mean HbA1c (10.2% vs 7.3%, respectively; P < 0.0001) and mean FBG (12.0 vs 7.6 mmol/L, respectively; P < 0.0001). Number of patients with HbA1c <7% increased from T0 (4.5%) to T6 (46.8%). Reasons for not achieving target HbA1c included poor diabetes education (50.7%), non-compliance to OADs (21.4%), and fear of hypoglycemia (19.7%). Conclusion Marked reductions in HbA1c and FBG are achievable in T2DM patients managed with OADs. However, patient education and compliance are important for achieving and maintaining treatment targets. 摘要 背景 在2型糖尿病（T2DM）患者中评估他们的基线特征、血糖控制情况以及口服降糖药物（OAD）使用情况。 方法 这项多国参与的观察研究招募的患者年龄≥21岁，他们是新诊断的和/或使用OAD单药治疗小于6个月并且血糖控制不佳的糖尿病患者。在横断层面上，要收集人口统计学数据、医疗史、糖尿病并发症以及合并症、OAD治疗方案、HbA1c以及空腹血糖（FBG）。在纵向层面上评估使用磺脲（SU）治疗的患者6个月随访结果，另外还要收集为什么没有达到HbA1c目标的数据。 结果 在招募的1487名患者（平均[±SD]年龄为52.0±11.6岁；46.7%为男性；平均BMI为25.8±4.4 kg/m2）中，75.9%为新诊断的糖尿病，73.3%有中心性肥胖，43.8%有高血压，并且60.5%有血脂紊乱。平均HbA1c为9.8±2.4%，平均FBG为11.3±4.3mmol/L。在T0 （基线时） 与T6 （第6个月随访时），分别有99.8% （n=1066）与97.1% （n=830） 的患者接受SU治疗。从T0至T6平均HbA1c（10.2% vs 7.3%；P < 0.0001）与平均FBG（分别为12.0 mmol/L vs 7.6 mmol/L；P < 0.0001）都有所下降。HbA1c < 7%的患者数量从T0（4.5%）至T6（46.8%）有所增加。没有达到HbA1c目标的原因包括糖尿病教育较差（50.7%）、使用OADs的依从性较差（21.4%）以及害怕发生低血糖（19.7%）。 结论 T2DM患者使用OADs治疗后HbA1c与FBG都获得了显著下降。然而，对于达到与维持治疗目标来说患者的教育以及依从性也非常重要。